Agile Therapeutics - AGRX Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AGRX shares.
View AGRX analyst ratings or view top-rated stocks.

2 analysts have issued 1 year target prices for Agile Therapeutics' shares. Their AGRX share price forecasts range from $100.00 to $100.00. On average, they expect the company's stock price to reach $100.00 in the next twelve months. This suggests a possible upside of 34,029.7% from the stock's current price.
View analysts price targets for AGRX or view top-rated stocks among Wall Street analysts.

Agile Therapeutics' stock was trading at $19.5240 at the beginning of the year. Since then, AGRX shares have decreased by 98.5% and is now trading at $0.2930.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our AGRX earnings forecast.

Agile Therapeutics, Inc. (NASDAQ:AGRX) announced its quarterly earnings data on Thursday, August, 11th. The specialty pharmaceutical company reported ($2.71) EPS for the quarter. The specialty pharmaceutical company had revenue of $2.13 million for the quarter, compared to analysts' expectations of $2.13 million. Agile Therapeutics had a negative trailing twelve-month return on equity of 1,016.70% and a negative net margin of 958.70%. During the same period last year, the firm posted ($8.00) earnings per share.

Agile Therapeutics's stock reverse split on Wednesday, April 27th 2022. The 1-40 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Agile Therapeutics investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Nabriva Therapeutics (NBRV), AcelRx Pharmaceuticals (ACRX), Micron Technology (MU) and Novavax (NVAX).

Agile Therapeutics trades on the NASDAQ under the ticker symbol "AGRX."

Shares of AGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AGRX stock can currently be purchased for approximately $0.29.

Agile Therapeutics (NASDAQ:AGRX) has a market capitalization of $11.43 million and generates $4.10 million in revenue each year. The specialty pharmaceutical company earns $-74,890,000.00 in net income (profit) each year or ($21.69) on an earnings per share basis.

Agile Therapeutics' mailing address is 101 POOR FARM ROAD, PRINCETON NJ, 08540. The official website for the company is www.agiletherapeutics.com. The specialty pharmaceutical company can be reached via phone at (609) 683-1880 or via email at info@agiletherapeutics.com.